Accounting for competing risks in randomized controlled trials: a review and recommendations for improvement

Statistics in Medicine

Volumn 36, Issue 8, 2017, Pages 1203-1209

  Austin, Peter C ^a,b,c   Fine, Jason P ^d,e  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Canada   (Canada)

^d University of North Carolina at Chapel Hill   (United States)

^e University of North Carolina at Chapel Hill   (United States)

Author keywords

competing risks; randomized controlled trial; RCT; survival analysis; systematic review

Indexed keywords

HUMAN; SURVIVAL ANALYSIS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STANDARDS; STATISTICAL ANALYSIS; STATISTICS; TOTAL QUALITY MANAGEMENT;

DATA INTERPRETATION, STATISTICAL; HUMANS; QUALITY IMPROVEMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STATISTICS AS TOPIC; SURVIVAL ANALYSIS;

EID: 85014337950     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.7215     Document Type: Article

References (25)

1. Austin PC, Manca A, Zwarenstein M, Juurlink DN, Stanbrook MB. A substantial and confusing variation exists in handling of baseline covariates in randomized controlled trials: a review of trials published in leading medical journals. Journal of Clinical Epidemiology 2010; 63(2):142–153.
2. Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation 2016; 133:601–609.
3. Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. American Journal of Epidemiology 2009; 170(2):244–256.
4. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Statistics in Medicine 2007; 26(11):2389–2430.
5. Cox D, Oakes D. Analysis of Survival Data. Chapman & Hall: London, 1984.
6. Piantadosi S. Clinical Trials: A Methodological Perspective. John Wiley & Sons: Hoboken, NJ, 2005.
7. Cook TD. DeMets DL. Boca Raton, FL: Introduction to Statistical Methods for Clinical Trials. Chapman & Hall/CRC, 2008.
8. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. The Annals of Statistics 1988; 16:1141–1154.
9. Wolbers M, Koller MT, Stel VS, Schaer B, Jager KJ, Leffondre K, Heinze G. Competing risks analyses: objectives and approaches. European Heart Journal 2014; 35(42):2936–2941.
10. Schulz KF, Altman DG, Moher D. Consort 2010 Statement: updated guidelines for reporting parallel group randomised trials. British Medical Journal 2010; 340:c332.
11. http://www.bmj.com/about-bmj/resources-authors/article-types/research, n.d. [Accessed on 27 April 2016]
12. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. New England Journal of Medicine 1988; 318:1728–1733.
13. Schechtman E. Odds ratio, relative risk, absolute risk reduction, and the number needed to treat - which of these should we use? Value in Health 2002; 5:431–436.
14. Sinclair JC, Bracken MB. Clinically useful measures of effect in binary analyses of randomized trials. Journal of Clinical Epidemiology 1994; 47(8):881–889.
15. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999; 319(7223):1492–1495.
16. Cox D. Regression models and life tables (with discussion). Journal of the Royal Statistical Society - Series B 1972; 34:187–220.
17. Royle PL, Waugh NR. Making literature searches easier: a rapid and sensitive search filter for retrieving randomized controlled trials from PubMed. Diabetic Medicine 2007; 24(3):308–311.
18. Varadham R, Weiss CO, Segal JB, Wu AW, Scharfstein D, Boyd C. Evaluating Health Outsomes in the Presence of Competing Risks. Medical Care 2010; 48(6 Suppl 1):S96–S105.
19. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Statisics in Medicine 1993; 12(8):737–751.
20. Gouskova NA, Kundu S, Imrey PB, Fine JP. Number needed to treat for time-to-event data with competing risks. Statistics in Medicine 2014; 33(2):181–192.
21. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association 1999; 94:496–509.
22. Latouche A, Allignol A, Beyersmann J, Labopin M, Fine JP. A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. Journal of Clinical Epidemiology 2013; 66(6):648–653.
23. Austin PC, Lee DS, D'Agostino RB, Fine JP. Developing points-based risk-scoring systems in the presence of competing risks. Statistics in Medicine 2016; 35(22):4056–4072.
24. van Walraven C, McAlister FA. Competing risk bias was common in Kaplan-Meier risk estimates published in prominent medical journals. Journal of Clinical Epidemiology 2016; 69:170–173.
25. Koller MT, Raatz H, Steyerberg EW, Wolbers M. Competing risks and the clinical community: irrelevance or ignorance? Statistics in Medicine 2012; 31(11–12):1089–1097.